Fig. 5

Profile of plasma cytokines, chemokines and growth factors in the patients during different clinical stages. Comparison between groups (UC-MSCs vs Placebo) and evaluated time points (baseline, days 2, 4, 6, 14 and 2 and 4 months). A Heatmap jointly comparing all analytes evaluated over the treatment time, either with cell therapy (UC-MSCs group) or placebo. Graphs show the results of some analytes separately, comparing the UC-MSC (red line) and placebo (blue line) groups over time. The bars show standard deviations (SD), and the broken line is the trend line fitted to the data. B Granulocyte–Macrophage Colony-Stimulating Factor (GM‐CSF); C Interleukin 2 (IL-2); D Macrophage Inflammatory Protein 1-Alpha (MIP1a/CCL3); E Tumor Necrosis Factor (TNF); F Interleukin 6 (IL-6); G Interleukin 8 (IL-8); H Interleukin 10 (IL-10); I Monocyte chemoattractant protein-1 (MCP1-CCL2); J Interleukin 7 (IL-7). Abbreviations: UC-MSCs, Umbilical Cord Mesenchymal Stromal Cells. *p ≤ 0.04 and **p ≤ 0.02 for comparison between groups. Statistical differences inside groups, longitudinal follow-up, were not depicted in the graphs but indicated in the main text